Market Overview

Even Exact Sciences Bulls Wonder If Expectations Are Lofty

Share:
Even Exact Sciences Bulls Wonder If Expectations Are Lofty

EXACT Sciences Corporation (NASDAQ: EXAS) shares have been on a heady run this year. Despite the sell side's optimism on the company's fundamentals, analysts have become wary of Exact's astronomical valuation, with the company holding its highest valuation since the summer of 2015.

The Analyst & Rating

Baird analyst Catherine Ramsey Schulte downgraded shares of Exact Sciences from Outperform to Neutral, with a price target of $56.

The Thesis

Exact Sciences has continued to report impressive quarters and steadily improving utilization, Ramsey Schulte said in a Monday note. Cologuard's positioning in quality measures and insurance coverage is strong, the analyst said. (See Ramsey Schulte's track record here.)

Expectations going into 2018 are high, according to Baird. Using a $450 average selling price, or ASP, estimate for 2018, the Street estimate for Exact sits at 930,000 completed tests versus Baird's estimate of 874,797.

The gap could be magnified further when guiding for the full year, Ramsey Schulte said.

Exact is in the habit of guiding conservatively and then beating its guidance, the analyst said. The company's guidance range for the fourth quarter suggests that it might be attempting to rein in expectations a bit, the Ramsey Schulte said.

"With a $7 billion-plus market cap, it certainly feels like big numbers are expected," she said. 

"We continue to have a very positive outlook on the business, but believe it's worth staying on the sidelines until expectations for 2018 have been set."

The Price Action

At the time of writing, shares of Exact Sciences were shedding 3.45 percent to $58.29.

The stock is up a staggering 336 percent year-to-date. 

Related Links: 

Risk-Reward Still Suggests Exact Sciences Is A Buy, But Be Cautious

Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Photo courtesy of Exact Sciences. 

Latest Ratings for EXAS

DateFirmActionFromTo
Jan 2020Initiates Coverage OnBuy
Nov 2019Initiates Coverage OnBuy
Oct 2019MaintainsBuy

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: Baird Catherine Ramsey SchulteAnalyst Color Downgrades Analyst Ratings Best of Benzinga

 

Related Articles (EXAS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
VALB of A SecuritiesMaintains5.0
HALB of A SecuritiesMaintains28.0
PPLB of A SecuritiesMaintains35.0
PNWB of A SecuritiesMaintains97.0
IRBTB of A SecuritiesMaintains56.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com